Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECCO 2017 | Renal cell carcinoma: the Emulsion and CheckMate 214 trials

Laurence Albiges • 27 Jan 2017
ECCO 2017
Kidney Cancer
CheckMate 214 Emulsion

Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses promising new trials in the treatment of renal cell carcinoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. The results of the randomised Phase II Emulsion trial (NCT02498665) and the Phase III CheckMate 214 (NCT02231749) investigating the combination of VEGF inhibitors and PDL1 inhibitors will soon be released. These results have the potential to challenge the first-line standard of care.

More from Laurence Albiges

LITESPARK-005: Belzutifan versus everolimus in ccRCC
2:48
LITESPARK-005: Belzutifan versus everolimus in ccRCC
Laurence Albiges • 21 Oct 2023
Biomarker development in RCC and UC
4:21
Biomarker development in RCC and UC
Laurence Albiges • 23 Sep 2021
Current and emerging treatment strategies for patients with mccRCC
2:24
Current and emerging treatment strategies for patients with mccRCC
Laurence Albiges • 23 Sep 2021
BIONIKK: the first trial study in mccRCC
1:50
BIONIKK: the first trial study in mccRCC
Laurence Albiges • 18 Sep 2020

Related Videos

How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
Improving emotional health assessment in patients with kidney cancer
0:57
Improving emotional health assessment in patients with kidney cancer
Eric Jonasch • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals